Review

Novel insights on diagnosis, cause and treatment of diabetic neuropathy: Focus on painful diabetic neuropathy

Mitra Tavakoli, Omar Asghar, Uazman Alam, Ioannis N. Petropoulos, Hassan Fadavi, Rayaz Malik

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Diabetic neuropathy is common, under or misdiagnosed, and causes substantial morbidity with increased mortality. Defining and developing sensitive diagnostic tests for diabetic neuropathy is not only key to implementing earlier interventions but also to ensure that the most appropriate endpoints are employed in clinical intervention trials. This is critical as many potentially effective therapies may never progress to the clinic, not due to a lack of therapeutic effect, but because the endpoints were not sufficiently sensitive or robust to identify benefit. Apart from improving glycaemic control, there is no licensed treatment for diabetic neuropathy, however, a number of pathogenetic pathways remain under active study. Painful diabetic neuropathy is a cause of considerable morbidity and whilst many pharmacological and nonpharmacological interventions are currently used, only two are approved by the US Food and Drug Administration. We address the important issue of the ‘placebo effect' and also consider potential new pharmacological therapies as well as nonpharmacological interventions in the treatment of painful diabetic neuropathy.

Original languageEnglish
Pages (from-to)69-88
Number of pages20
JournalTherapeutic Advances in Endocrinology and Metabolism
Volume1
Issue number2
DOIs
Publication statusPublished - 2010
Externally publishedYes

Fingerprint

Diabetic Neuropathies
Pharmacology
Morbidity
Placebo Effect
Therapeutic Uses
United States Food and Drug Administration
Diagnostic Errors
Routine Diagnostic Tests
Clinical Trials
Mortality
Therapeutics

Keywords

  • diabetic neuropathy
  • diagnosis
  • nonpharmacological treatment
  • painful diabetic neuropathy
  • pharmacological

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Review : Novel insights on diagnosis, cause and treatment of diabetic neuropathy: Focus on painful diabetic neuropathy. / Tavakoli, Mitra; Asghar, Omar; Alam, Uazman; Petropoulos, Ioannis N.; Fadavi, Hassan; Malik, Rayaz.

In: Therapeutic Advances in Endocrinology and Metabolism, Vol. 1, No. 2, 2010, p. 69-88.

Research output: Contribution to journalReview article

Tavakoli, Mitra ; Asghar, Omar ; Alam, Uazman ; Petropoulos, Ioannis N. ; Fadavi, Hassan ; Malik, Rayaz. / Review : Novel insights on diagnosis, cause and treatment of diabetic neuropathy: Focus on painful diabetic neuropathy. In: Therapeutic Advances in Endocrinology and Metabolism. 2010 ; Vol. 1, No. 2. pp. 69-88.
@article{8b18422e8d7e4391a8a845e7ed4ca33d,
title = "Review: Novel insights on diagnosis, cause and treatment of diabetic neuropathy: Focus on painful diabetic neuropathy",
abstract = "Diabetic neuropathy is common, under or misdiagnosed, and causes substantial morbidity with increased mortality. Defining and developing sensitive diagnostic tests for diabetic neuropathy is not only key to implementing earlier interventions but also to ensure that the most appropriate endpoints are employed in clinical intervention trials. This is critical as many potentially effective therapies may never progress to the clinic, not due to a lack of therapeutic effect, but because the endpoints were not sufficiently sensitive or robust to identify benefit. Apart from improving glycaemic control, there is no licensed treatment for diabetic neuropathy, however, a number of pathogenetic pathways remain under active study. Painful diabetic neuropathy is a cause of considerable morbidity and whilst many pharmacological and nonpharmacological interventions are currently used, only two are approved by the US Food and Drug Administration. We address the important issue of the ‘placebo effect' and also consider potential new pharmacological therapies as well as nonpharmacological interventions in the treatment of painful diabetic neuropathy.",
keywords = "diabetic neuropathy, diagnosis, nonpharmacological treatment, painful diabetic neuropathy, pharmacological",
author = "Mitra Tavakoli and Omar Asghar and Uazman Alam and Petropoulos, {Ioannis N.} and Hassan Fadavi and Rayaz Malik",
year = "2010",
doi = "10.1177/2042018810370954",
language = "English",
volume = "1",
pages = "69--88",
journal = "Therapeutic Advances in Endocrinology and Metabolism",
issn = "2042-0188",
publisher = "Sage Periodicals Press",
number = "2",

}

TY - JOUR

T1 - Review

T2 - Novel insights on diagnosis, cause and treatment of diabetic neuropathy: Focus on painful diabetic neuropathy

AU - Tavakoli, Mitra

AU - Asghar, Omar

AU - Alam, Uazman

AU - Petropoulos, Ioannis N.

AU - Fadavi, Hassan

AU - Malik, Rayaz

PY - 2010

Y1 - 2010

N2 - Diabetic neuropathy is common, under or misdiagnosed, and causes substantial morbidity with increased mortality. Defining and developing sensitive diagnostic tests for diabetic neuropathy is not only key to implementing earlier interventions but also to ensure that the most appropriate endpoints are employed in clinical intervention trials. This is critical as many potentially effective therapies may never progress to the clinic, not due to a lack of therapeutic effect, but because the endpoints were not sufficiently sensitive or robust to identify benefit. Apart from improving glycaemic control, there is no licensed treatment for diabetic neuropathy, however, a number of pathogenetic pathways remain under active study. Painful diabetic neuropathy is a cause of considerable morbidity and whilst many pharmacological and nonpharmacological interventions are currently used, only two are approved by the US Food and Drug Administration. We address the important issue of the ‘placebo effect' and also consider potential new pharmacological therapies as well as nonpharmacological interventions in the treatment of painful diabetic neuropathy.

AB - Diabetic neuropathy is common, under or misdiagnosed, and causes substantial morbidity with increased mortality. Defining and developing sensitive diagnostic tests for diabetic neuropathy is not only key to implementing earlier interventions but also to ensure that the most appropriate endpoints are employed in clinical intervention trials. This is critical as many potentially effective therapies may never progress to the clinic, not due to a lack of therapeutic effect, but because the endpoints were not sufficiently sensitive or robust to identify benefit. Apart from improving glycaemic control, there is no licensed treatment for diabetic neuropathy, however, a number of pathogenetic pathways remain under active study. Painful diabetic neuropathy is a cause of considerable morbidity and whilst many pharmacological and nonpharmacological interventions are currently used, only two are approved by the US Food and Drug Administration. We address the important issue of the ‘placebo effect' and also consider potential new pharmacological therapies as well as nonpharmacological interventions in the treatment of painful diabetic neuropathy.

KW - diabetic neuropathy

KW - diagnosis

KW - nonpharmacological treatment

KW - painful diabetic neuropathy

KW - pharmacological

UR - http://www.scopus.com/inward/record.url?scp=78650229065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650229065&partnerID=8YFLogxK

U2 - 10.1177/2042018810370954

DO - 10.1177/2042018810370954

M3 - Review article

VL - 1

SP - 69

EP - 88

JO - Therapeutic Advances in Endocrinology and Metabolism

JF - Therapeutic Advances in Endocrinology and Metabolism

SN - 2042-0188

IS - 2

ER -